In the United States, the safety and efficacy of prescription and over-the-counter drugs are a top priority for our government, medical professionals, and pharmaceutical companies. The Food and Drug Administration (FDA) is responsible for protecting public health by ensuring that any and all available medications are safe for human consumption, especially with regard to approving new medications or deciding whether or not a drug should be taken off the market. That even includes veterinary drugs and biological products as well. The cost of creating and testing a single drug can…
According to the Centers for Disease Control and Prevention (CDC), there are currently over 6.2 million confirmed cases of COVID-19 in the United States, and that number continues to rise for the time being. From wearing masks to sheltering-in-place, social distancing, and incessant hand-washing, every American has the ability to help our nation ebb the continued spread of the novel coronavirus. In addition to encouraging Americans to adopt strict sterilization habits and apply them to their daily routine, more aggressive and ambitious methods need to be implemented like increased COVID-19…
ELISpot is a method commonly used to detect cellular immune responses to viral vector-based gene therapies. We take a closer look at how the industry is working to harmonize best practices for developing & validating ELISpot assays for gene therapy development.
The best science demands the best people—and at BioAgilytix’s Boston lab, there’s no shortage of skilled and dedicated scientists. Get to know one of our expert flow cytometry scientists and longtime Boston team member, Benjamin Lamothe.
BioAgilytix’s CLIA Laboratory Director, Natalie Smith, outlines the differences between CLIA, CAP & COLA regulations & accreditations, and what they mean for laboratory testing quality.
In our recruitment process we are often asked by those coming from pharma & biotech careers, “what’s a day in the life like at a CRO?” Who better to ask than our own team members who have made the career transition themselves? We start the discussion with Dr. Jim McNally.
The concept of using pre-existing immunogenicity as an exclusion criteria for gene therapy clinical trials is changing. BioAgilytix’s Chief Scientific Officer, Dr. Jim McNally, explores why.
We recently sat down with Dr. Jim McNally for a Q&A to hear his "Behind the Science" perspectives on the industry and where he thinks BioAgilytix brings the most value to pharma & biotech customers.
We've compiled a guide to the presentations & forums our BioAgilytix team members will be participating in throughout the 2020 WRIB Virtual Meeting so you can join in the conversations too.
Did you know that our new General Manager, Europe, Dr. Frank Horling, was a client of BioAgilytix before joining our team? We asked him to share his perspectives on what it was like to be a BioAgilytix customer as well as what motivated him to join our lab in Hamburg, Germany.
